Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jul 24;83(4):467–472. doi: 10.1054/bjoc.2000.1292

Genomic alterations associated with loss of heterozygosity for TP53 in Li-Fraumeni syndrome fibroblasts

E C Burt 1, L A James 1, M J Greaves 1, J M Birch 2, J M Boyle 1, J M Varley 1
PMCID: PMC2374657  PMID: 10945493

Abstract

Studies of Li-Fraumeni syndrome fibroblasts heterozygous for germline TP53 mutations have shown that loss of heterozygosity (LOH) occurs during passaging and is associated with genomic instability, such as chromosomal aberrations and aneuploidy. to investigate the genomic changes associated with LOH in Li-Fraumeni (LF) fibroblasts, we have analysed cell strains at increasing population doublings (PD) using Comparative Genomic Hybridization (CGH). We have looked at three groups of cell strains: LF mutation-carrying strains which showed LOH for TP53, LF mutation-carrying strains which did not show LOH, and strains from normal individuals. Using CGH, we have detected loss of distinct chromosomal regions associated with LOH in 4 out of 5 mutation-carrying strains. In particular we have found loss of chromosomal regions containing genes involved in cell cycle control or senescence, including loss of 9p and 17p in these strains. Other recurrent changes included loss of chromosomes 4q and 6q, regions shown to contain one or more tumour suppressor genes. No genomic alterations were detected at cumulative PD in the normal strains or in the LF mutation-carrying strains which did not show LOH for TP53. We have also analysed the three groups of strains for microsatellite instability and somatic TP53 mutations, and have found genetic alterations in only one strain. © 2000 Cancer Research Campaign

Keywords: Li-Fraumeni Syndrome, CGH, LOH, TP53, fibroblasts

Full Text

The Full Text of this article is available as a PDF (335.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bentz M., Plesch A., Stilgenbauer S., Döhner H., Lichter P. Minimal sizes of deletions detected by comparative genomic hybridization. Genes Chromosomes Cancer. 1998 Feb;21(2):172–175. [PubMed] [Google Scholar]
  2. Bertram M. J., Bérubé N. G., Hang-Swanson X., Ran Q., Leung J. K., Bryce S., Spurgers K., Bick R. J., Baldini A., Ning Y. Identification of a gene that reverses the immortal phenotype of a subset of cells and is a member of a novel family of transcription factor-like genes. Mol Cell Biol. 1999 Feb;19(2):1479–1485. doi: 10.1128/mcb.19.2.1479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Birch J. M., Hartley A. L., Tricker K. J., Prosser J., Condie A., Kelsey A. M., Harris M., Jones P. H., Binchy A., Crowther D. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res. 1994 Mar 1;54(5):1298–1304. [PubMed] [Google Scholar]
  4. Boyle J. M., Greaves M. J., Camplejohn R. S., Birch J. M., Roberts S. A., Varley J. M. Radiation-induced G1 arrest is not defective in fibroblasts from Li-Fraumeni families without TP53 mutations. Br J Cancer. 1999 Apr;79(11-12):1657–1664. doi: 10.1038/sj.bjc.6690265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Boyle J. M., Mitchell E. L., Greaves M. J., Roberts S. A., Tricker K., Burt E., Varley J. M., Birch J. M., Scott D. Chromosome instability is a predominant trait of fibroblasts from Li-Fraumeni families. Br J Cancer. 1998 Jun;77(12):2181–2192. doi: 10.1038/bjc.1998.364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bryce S. D., Forsyth N. R., Fitzsimmons S. A., Clark L. J., Bertram M. J., Cuthbert A. P., Newbold R. F., Pereira-Smith O. M., Parkinson E. K. Genetic and functional analyses exclude mortality factor 4 (MORF4) as a keratinocyte senescence gene. Cancer Res. 1999 May 1;59(9):2038–2040. [PubMed] [Google Scholar]
  7. Cairns P., Polascik T. J., Eby Y., Tokino K., Califano J., Merlo A., Mao L., Herath J., Jenkins R., Westra W. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet. 1995 Oct;11(2):210–212. doi: 10.1038/ng1095-210. [DOI] [PubMed] [Google Scholar]
  8. Couch F. J., Wang X. Y., Wu G. J., Qian J., Jenkins R. B., James C. D. Localization of PS6K to chromosomal region 17q23 and determination of its amplification in breast cancer. Cancer Res. 1999 Apr 1;59(7):1408–1411. [PubMed] [Google Scholar]
  9. Dib C., Fauré S., Fizames C., Samson D., Drouot N., Vignal A., Millasseau P., Marc S., Hazan J., Seboun E. A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature. 1996 Mar 14;380(6570):152–154. doi: 10.1038/380152a0. [DOI] [PubMed] [Google Scholar]
  10. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. doi: 10.1126/science.1905840. [DOI] [PubMed] [Google Scholar]
  11. James L. A. Comparative genomic hybridization as a tool in tumour cytogenetics. J Pathol. 1999 Mar;187(4):385–395. doi: 10.1002/(SICI)1096-9896(199903)187:4<385::AID-PATH290>3.0.CO;2-5. [DOI] [PubMed] [Google Scholar]
  12. James L. A., Mitchell E. L., Menasce L., Varley J. M. Comparative genomic hybridisation of ductal carcinoma in situ of the breast: identification of regions of DNA amplification and deletion in common with invasive breast carcinoma. Oncogene. 1997 Mar 6;14(9):1059–1065. doi: 10.1038/sj.onc.1200923. [DOI] [PubMed] [Google Scholar]
  13. Kallioniemi A., Kallioniemi O. P., Sudar D., Rutovitz D., Gray J. W., Waldman F., Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science. 1992 Oct 30;258(5083):818–821. doi: 10.1126/science.1359641. [DOI] [PubMed] [Google Scholar]
  14. Kamb A., Gruis N. A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S. V., Stockert E., Day R. S., 3rd, Johnson B. E., Skolnick M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994 Apr 15;264(5157):436–440. doi: 10.1126/science.8153634. [DOI] [PubMed] [Google Scholar]
  15. Knuutila S., Björkqvist A. M., Autio K., Tarkkanen M., Wolf M., Monni O., Szymanska J., Larramendy M. L., Tapper J., Pere H. DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol. 1998 May;152(5):1107–1123. [PMC free article] [PubMed] [Google Scholar]
  16. Lane D. P., Crawford L. V. T antigen is bound to a host protein in SV40-transformed cells. Nature. 1979 Mar 15;278(5701):261–263. doi: 10.1038/278261a0. [DOI] [PubMed] [Google Scholar]
  17. Levine A. J., Momand J., Finlay C. A. The p53 tumour suppressor gene. Nature. 1991 Jun 6;351(6326):453–456. doi: 10.1038/351453a0. [DOI] [PubMed] [Google Scholar]
  18. Li F. P., Fraumeni J. F., Jr, Mulvihill J. J., Blattner W. A., Dreyfus M. G., Tucker M. A., Miller R. W. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988 Sep 15;48(18):5358–5362. [PubMed] [Google Scholar]
  19. Mao L., Merlo A., Bedi G., Shapiro G. I., Edwards C. D., Rollins B. J., Sidransky D. A novel p16INK4A transcript. Cancer Res. 1995 Jul 15;55(14):2995–2997. [PubMed] [Google Scholar]
  20. Morelli C., Sherratt T., Trabanelli C., Rimessi P., Gualandi F., Greaves M. J., Negrini M., Boyle J. M., Barbanti-Brodano G. Characterization of a 4-Mb region at chromosome 6q21 harboring a replicative senescence gene. Cancer Res. 1997 Oct 1;57(19):4153–4157. [PubMed] [Google Scholar]
  21. Noble J. R., Rogan E. M., Neumann A. A., Maclean K., Bryan T. M., Reddel R. R. Association of extended in vitro proliferative potential with loss of p16INK4 expression. Oncogene. 1996 Sep 19;13(6):1259–1268. [PubMed] [Google Scholar]
  22. Parsons R., Myeroff L. L., Liu B., Willson J. K., Markowitz S. D., Kinzler K. W., Vogelstein B. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res. 1995 Dec 1;55(23):5548–5550. [PubMed] [Google Scholar]
  23. Piper J., Rutovitz D., Sudar D., Kallioniemi A., Kallioniemi O. P., Waldman F. M., Gray J. W., Pinkel D. Computer image analysis of comparative genomic hybridization. Cytometry. 1995 Jan 1;19(1):10–26. doi: 10.1002/cyto.990190104. [DOI] [PubMed] [Google Scholar]
  24. Quelle D. E., Zindy F., Ashmun R. A., Sherr C. J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 1995 Dec 15;83(6):993–1000. doi: 10.1016/0092-8674(95)90214-7. [DOI] [PubMed] [Google Scholar]
  25. Rogan E. M., Bryan T. M., Hukku B., Maclean K., Chang A. C., Moy E. L., Englezou A., Warneford S. G., Dalla-Pozza L., Reddel R. R. Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol. 1995 Sep;15(9):4745–4753. doi: 10.1128/mcb.15.9.4745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Stone S., Jiang P., Dayananth P., Tavtigian S. V., Katcher H., Parry D., Peters G., Kamb A. Complex structure and regulation of the P16 (MTS1) locus. Cancer Res. 1995 Jul 15;55(14):2988–2994. [PubMed] [Google Scholar]
  27. Tainsky M. A., Bischoff F. Z., Strong L. C. Genomic instability due to germline p53 mutations drives preneoplastic progression toward cancer in human cells. Cancer Metastasis Rev. 1995 Mar;14(1):43–48. doi: 10.1007/BF00690210. [DOI] [PubMed] [Google Scholar]
  28. Varley J. M., McGown G., Thorncroft M., James L. A., Margison G. P., Forster G., Evans D. G., Harris M., Kelsey A. M., Birch J. M. Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors. Am J Hum Genet. 1999 Oct;65(4):995–1006. doi: 10.1086/302575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Varley J. M., McGown G., Thorncroft M., Santibanez-Koref M. F., Kelsey A. M., Tricker K. J., Evans D. G., Birch J. M. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res. 1997 Aug 1;57(15):3245–3252. [PubMed] [Google Scholar]
  30. Velasco-Miguel S., Buckbinder L., Jean P., Gelbert L., Talbott R., Laidlaw J., Seizinger B., Kley N. PA26, a novel target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes. Oncogene. 1999 Jan 7;18(1):127–137. doi: 10.1038/sj.onc.1202274. [DOI] [PubMed] [Google Scholar]
  31. Wahl G. M., Linke S. P., Paulson T. G., Huang L. C. Maintaining genetic stability through TP53 mediated checkpoint control. Cancer Surv. 1997;29:183–219. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES